The FDA approved it in 2016, but the question remains: Is real-world evidence a suitable substitute for randomized clinical trials? Knect365 interviews Dan Danielson, Senior Director of the Access Experience Team at Precision for Value, on the opportunities and challenges of real-world evidence.
Managed Healthcare Executive asked leaders to describe the most important factors in building a successful team. Dan Renick, President, Precision Value & Health, stresses the value of investing in the team. See why—and get other leadership insights in this engaging slideshow.
ADDITIONS OF KEY FORMER PAYER DECISION MAKERS COX, DANIELSON, AND LOPATA WILL PROVIDE CLIENTS WITH WINNING STRATEGIES TO ADDRESS LATEST TRENDS IN
RAPIDLY CHANGING HEALTHCARE MARKETPLACE
As the largest payer in the US, the government is understandably concerned about the high price of drugs. How will the rebate debate end? In this PM360 article, Precision for Value VP Andy Cournoyer describes a stumbling block—administrative fees—and posits some solutions.
As copay accumulator programs have gained increasing traction, pharma companies have been working to find ways around them. PM360 asked six experts for their insights, including Sejal Jonas, Senior Director, Access Experience Team, Precision for Value. She predicts a 25-50% adoption by employers over the next two years.
Formulary Watch reports that the FDA has expanded the indication for the Pfizer drug palbociclib to treat breast cancer in male patients. Janet Serluco, VP, Access Experience Team, Oncology Lead at Precision Medicine Group, comments on the implications for patients and for Pfizer.
As legislative efforts have changed the 340 Drug Discount Program, payers, specialty pharmacies and health systems have been impacted. Precision for Value experts Dominic Galante, Chief Medical Officer, and Linda R. Bolland, senior advisor, discuss the factors affecting the program today in an exclusive video on Specialty Pharmacy Continuum.
More than 90 million people are covered by payers with a copay accumulator program—but patient advocates are fighting back. Jeremey Shafer, Senior VP, Access Experience Team, Precision for Value, believes the advocates will be successful. Discover why in Radar on Specialty Pharmacy. (more…)
Gene therapies offer tremendous promise—yet their high upfront cost has been a challenge for payers. Kellie Rademacher, Precision for Value’s VP, Access Experience Team, outlined the pros and cons in a talk at the Association of Managed Care Pharmacy Annual Meeting; Managed Healthcare Executive reports on it.
Authorized generics allow drug manufacturers to tout a cost-conscious option—and ultimately to compete with other generics. But what does that mean for payers and consumers? Precision’s Jeremey Shafer, senior VP and director of the Access Experience Team, shares insights on the pricing intricacies in this Spotlight on Market Access article.
The Precision Value & Health family of brands is now Precision AQ
Precision AQ helps life sciences companies navigate the complexities of commercialization across a product’s lifecycle. Our team is comprised of experts, advisors, and creators working to ensure patients have access to life-changing medicines.
Our global offerings include:
Our name, which stands for Precision Access Quotient, reflects our approach to removing barriers – fusing together science (IQ, or Intelligence Quotient) and empathy (EQ, or Emotional Quotient). The result is “AQ: Access Quotient”, a critical ingredient in navigating the therapy-to-patient journey informed by data-driven analytics and insights.
To find out more about our global services and our unified mission, empowering access to life-changing medicines for all, visit: Precision AQ
